The overarching goal of this work is not only to provide clinicians with updated evidence on the efficacy and safety of PSMA-TAT but also to underscore its potential to drive the design of prospective, randomised controlled trials and facilitate the introduction of this therapy into clinical practice, to the ultimate benefit of prostate cancer patients. The gene discussed is FOLH1; the disease is Familial prostate cancer.